Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

CIK cell cytotoxicity is a predictive biomarker for CIK cell immunotherapy in postoperative patients with hepatocellular carcinoma

Abstract

Adjuvant cytokine-induced killer (CIK) cell immunotherapy has shown potential in improving the prognosis of hepatocellular carcinoma (HCC) patients after curative resection. However, whether an individual could obtain survival benefit from CIK cell treatment remains unknown. In the present study, we focused on the characteristics of CIK cells and aimed to identify the best predictive biomarker for adjuvant CIK cell treatment in patients with HCC after surgery. This study included 48 patients with HCC treated with postoperative adjuvant CIK cell immunotherapy. The phenotype activity and cytotoxic activity of CIK cells were determined by flow cytometry and xCELLigence™ Real-Time Cell Analysis (RTCA) system, respectively. Correlation analysis revealed that the cytotoxic activity of CIK cells was significantly negative correlated with the percentage of CD3+ CD4+ cell subsets, but significantly positive correlated with CD3-CD56+ and CD3+ CD56+ cell subsets. Survival analysis showed that there were no significant associations between patients’ prognosis and the phenotype of CIK cells. By contrast, there was statistically significant improvement in recurrence-free survival (RFS) and overall survival (OS) for patients with high cytotoxic activity of CIK cells as compared with those with low cytotoxic activity of CIK cells. Univariate and multivariate analyses indicated that CIK cell cytotoxicity was an independent prognostic factor for RFS and OS. In conclusion, a high cytotoxic activity of CIK cells can serve as a valuable biomarker for adjuvant CIK cell immunotherapy of HCC patients after surgery.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Abbreviations

CI:

Cellular index

CIK cells:

Cytokine-induced killer cells

HCC:

Hepatocellular carcinoma

OS:

Overall survival

RFS:

Recurrence-free survival

RTCA system:

Real-Time Cell Analysis system

References

  1. 1.

    Torre LA, Bray F, Siegel RL et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108. https://doi.org/10.3322/caac.21262

  2. 2.

    Page AJ, Cosgrove DC, Philosophe B et al (2014) Hepatocellular carcinoma: diagnosis, management, and prognosis. Surg Oncol Clin N Am 23(2):289–311. https://doi.org/10.1016/j.soc.2013.10.006

  3. 3.

    Lai EC, Fan ST, Lo CM et al (1995) Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg 221(3):291–298

  4. 4.

    Dhir M, Melin AA, Douaiher J et al (2016) A review and update of treatment options and controversies in the management of hepatocellular carcinoma. Ann Surg 263(6):1112–1125. https://doi.org/10.1097/SLA.0000000000001556

  5. 5.

    Samuel M, Chow PK, Chan Shih-Yen E et al (2009) Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev (1):CD001199 https://doi.org/10.1002/14651858.CD001199.pub2

  6. 6.

    Xiao Z, Wang CQ, Feng JH et al (2019) Effectiveness and safety of chemotherapy with cytokine-induced killer cells in non-small cell lung cancer: a systematic review and meta-analysis of 32 randomized controlled trials. Cytotherapy 21(2):125–147. https://doi.org/10.1016/j.jcyt.2018.10.011

  7. 7.

    Zhu J, Li R, Tiselius E et al (2017) Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent. Cochrane Database Syst Rev 12:CD011300 https://doi.org/10.1002/14651858.CD011300.pub2

  8. 8.

    Zhou X, Mo X, Qiu J et al (2018) Chemotherapy combined with dendritic cell vaccine and cytokine-induced killer cells in the treatment of colorectal carcinoma: a meta-analysis. Cancer Manag Res 10:5363–5372. https://doi.org/10.2147/CMAR.S173201

  9. 9.

    Ma Y, Zhang Z, Tang L et al (2012) Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis. Cytotherapy 14(4):483–493. https://doi.org/10.3109/14653249.2011.649185

  10. 10.

    Schmeel LC, Schmeel FC, Coch C et al (2015) Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 141(5):839–849. https://doi.org/10.1007/s00432-014-1864-3

  11. 11.

    Chen C, Ma YH, Zhang YT et al (2018) Effect of dendritic cell-based immunotherapy on hepatocellular carcinoma: a systematic review and meta-analysis. Cytotherapy 20(8):975–989. https://doi.org/10.1016/j.jcyt.2018.06.002

  12. 12.

    Cao J, Kong FH, Liu X et al (2019) Immunotherapy with dendritic cells and cytokine-induced killer cells for hepatocellular carcinoma: a meta-analysis. World J Gastroenterol 25(27):3649–3663. https://doi.org/10.3748/wjg.v25.i27.3649

  13. 13.

    Lee JH, Lee JH, Lim YS et al (2015) Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology 148(7):1383–1391. https://doi.org/10.1053/j.gastro.2015.02.055

  14. 14.

    Lee JH, Lee JH, Lim YS et al (2019) Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up. Cancer Immunol Immunother 68(1):23–32. https://doi.org/10.1007/s00262-018-2247-4

  15. 15.

    Xu L, Wang J, Kim Y et al (2016) A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma. Oncoimmunology 5(3):e1083671. https://doi.org/10.1080/2162402X.2015.1083671

  16. 16.

    Pan QZ, Wang QJ, Dan JQ et al (2015) A nomogram for predicting the benefit of adjuvant cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma. Sci Rep 5:9202. https://doi.org/10.1038/srep09202

  17. 17.

    Mata-Molanes JJ, Sureda Gonzalez M, Valenzuela Jimenez B et al (2017) Cancer immunotherapy with cytokine-induced killer cells. Target Oncol 12(3):289–299. https://doi.org/10.1007/s11523-017-0489-2

  18. 18.

    Schmidt-Wolf IG, Negrin RS, Kiem HP et al (1991) Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174(1):139–149. https://doi.org/10.1084/jem.174.1.139

  19. 19.

    Pan K, Guan XX, Li YQ et al (2014) Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancer. Clin Cancer Res 20(11):3003–3011. https://doi.org/10.1158/1078-0432.CCR-14-0082

  20. 20.

    Pan QZ, Tang Y, Wang QJ et al (2015) Adjuvant cellular immunotherapy in patients with resected primary non-small cell lung cancer. Oncoimmunology 4(9):e1038017. https://doi.org/10.1080/2162402X.2015.1038017

  21. 21.

    Erskine CL, Henle AM, Knutson KL (2012) Determining optimal cytotoxic activity of human Her2neu specific CD8 T cells by comparing the Cr51 release assay to the xCELLigence system. J Vis Exp 66:e3683. https://doi.org/10.3791/3683

  22. 22.

    Messaoudene M, Fregni G, Fourmentraux-Neves E et al (2014) Mature cytotoxic CD56(bright)/CD16(+) natural killer cells can infiltrate lymph nodes adjacent to metastatic melanoma. Cancer Res 74(1):81–92. https://doi.org/10.1158/0008-5472.CAN-13-1303

  23. 23.

    Schmidt-Wolf IG, Lefterova P, Mehta BA et al (1993) Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 21(13):1673–1679

  24. 24.

    Lu PH, Negrin RS (1994) A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 153(4):1687–1696

  25. 25.

    Pan K, Li YQ, Wang W et al (2013) The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients. Ann Surg Oncol 20(13):4305–4311. https://doi.org/10.1245/s10434-013-3144-x

  26. 26.

    Zhang L, Wang J, Wei F et al (2016) Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients. Oncotarget 7(28):43604–43615. https://doi.org/10.18632/oncotarget.9871

  27. 27.

    Verneris MR, Karimi M, Baker J et al (2004) Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 103(8):3065–3072. https://doi.org/10.1182/blood-2003-06-2125

  28. 28.

    Li H, Yu JP, Cao S et al (2007) CD4+CD25+ regulatory T cells decreased the antitumor activity of cytokine-induced killer (CIK) cells of lung cancer patients. J Clin Immunol 27(3):317–326. https://doi.org/10.1007/s10875-007-9076-0

  29. 29.

    Huang L, Qiao G, Morse MA et al (2019) Predictive significance of T cell subset changes during ex vivo generation of adoptive cellular therapy products for the treatment of advanced non-small cell lung cancer. Oncol Lett 18(6):5717–5724. https://doi.org/10.3892/ol.2019.10964

Download references

Acknowledgements

This work was primarily supported by a grant from the National Key Research and Development Program of China (No. 2018YFC1313400), the National Natural Science Foundation of China (No. 81803079; 81402560; 81572865; 81472387), the Guangdong Natural Science Foundation (No. 2018A030310237), and the Guangdong Province Science and Technology Plan Project (No. 2017A020215029).

Author information

QZP and QL: data collection, assembly, and data analysis. YQZ, JJZ, QJW, YQL, JMG, YT, JH, and SPC: cell generation, and data analysis and interpretation. DSW and JCX: designed and directed the overall project. QZP, QL, DSW, and JCX: manuscript writing and final approval of the manuscript. All authors read and approved the manuscript.

Correspondence to De-Sheng Weng or Jian-Chuan Xia.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Ethical approval

The Institutional Review Board of the Sun Yat-sen University Cancer Center approved the study design (B2016-035-01). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 961 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Pan, Q., Liu, Q., Zhou, Y. et al. CIK cell cytotoxicity is a predictive biomarker for CIK cell immunotherapy in postoperative patients with hepatocellular carcinoma. Cancer Immunol Immunother (2020). https://doi.org/10.1007/s00262-020-02486-y

Download citation

Keywords

  • CIK cell immunotherapy
  • Hepatocellular carcinoma
  • Cytotoxicity
  • Prognosis